Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 347.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,308,199 shares of the biotechnology company’s stock after purchasing an additional 1,016,069 shares during the period. Federated Hermes Inc. owned about 1.34% of Sarepta Therapeutics worth $22,370,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Wellington Management Group LLP increased its stake in Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after buying an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of Sarepta Therapeutics by 2.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock worth $127,512,000 after acquiring an additional 41,408 shares during the period. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 3.0% in the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after acquiring an additional 55,076 shares in the last quarter. EcoR1 Capital LLC raised its stake in shares of Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock valued at $82,480,000 after acquiring an additional 522,386 shares in the last quarter. Finally, Aberdeen Group plc boosted its holdings in Sarepta Therapeutics by 91.1% in the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after purchasing an additional 592,125 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $22.17 on Wednesday. The company has a fifty day moving average of $20.91 and a two-hundred day moving average of $21.21. The company has a market capitalization of $2.32 billion, a PE ratio of -7.37 and a beta of 0.54. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $129.84. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Wedbush assumed coverage on Sarepta Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $32.00 price objective for the company. Royal Bank Of Canada raised their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a report on Wednesday, October 8th. Barclays dropped their price objective on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 5th. Finally, Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $33.68.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.